Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACET

Adicet Bio Inc

Mar 14 • 04:00PM ET

0.7826

Dollar change +0.0067
Percentage change 0.86	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP FATE NTLA ALLO AGIO GILD BLUE EDIT IMTX SGMO

| Held by: VTI VXF FESM IWC CNCR CHNA BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	20.96%	Shs Outstand	82.57M	Perf Week	-1.70%
Market Cap	64.71M	Forward P/E	-	EPS next Y	-1.33	Insider Trans	0.00%	Shs Float	65.35M	Perf Month	-9.68%
Income	-117.12M	PEG	-	EPS next Q	-0.33	Inst Own	50.68%	Short Float	4.81%	Perf Quarter	-26.17%
Sales	0.00M	P/S	-	EPS this Y	-14.39%	Inst Trans	-1.45%	Short Ratio	3.72	Perf Half Y	-45.27%
Book/sh	2.26	P/B	0.35	EPS next Y	12.58%	ROA	-54.79%	Short Interest	3.14M	Perf Year	-66.84%
Cash/sh	2.13	P/C	0.37	EPS next 5Y	5.15%	ROE	-65.65%	52W Range	0.74 - 2.43	Perf YTD	-18.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.74%	ROI	-58.35%	52W High	-67.79%	Beta	1.97
Dividend TTM	-	Quick Ratio	9.29	Sales past 5Y	342.10%	Gross Margin	-	52W Low	5.05%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	9.29	EPS Y/Y TTM	59.75%	Oper. Margin	-	RSI (14)	38.35	Volatility	7.44% 7.44%
Employees	152	Debt/Eq	0.09	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.57	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	53.85%	Payout	-	Rel Volume	0.13	Prev Close	0.78
Sales Surprise	-	EPS Surprise	10.29%	Sales Q/Q	-	Earnings	Mar 06 AMC	Avg Volume	845.77K	Price	0.78
SMA20	-10.88%	SMA50	-14.14%	SMA200	-35.22%	Trades		Volume	111,325	Change	0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Resumed	Guggenheim	Buy	$7
Sep-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-27-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-23	Downgrade	Guggenheim	Buy → Neutral
Jun-01-23	Downgrade	JP Morgan	Overweight → Neutral	$20 → $6
Sep-21-22	Initiated	JP Morgan	Overweight	$23
Mar-31-22	Initiated	SMBC Nikko	Outperform	$28
Mar-08-22	Initiated	Truist	Buy	$30
Mar-04-22	Initiated	Jefferies	Buy	$27
May-18-21	Initiated	BTIG Research	Buy	$34
Apr-23-21	Initiated	H.C. Wainwright	Buy	$27
Apr-14-21	Initiated	Canaccord Genuity	Buy	$28
Apr-08-21	Initiated	Guggenheim	Buy	$22
Nov-04-20	Initiated	B. Riley Securities	Buy	$30
Oct-27-20	Initiated	JMP Securities	Mkt Outperform	$30
Oct-16-20	Initiated	Wedbush	Outperform	$25

Show Previous Ratings

Mar-06-25 04:01PM	Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress (Business Wire) -5.90%
Mar-03-25 07:00AM	Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting (Business Wire) -5.70%
Feb-27-25 08:36AM	Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 (Investing.com)
07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) (Business Wire)
Feb-05-25 07:10AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement (Business Wire) +9.79%
06:06PM	Loading…
Jan-31-25 06:06PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-08-25 04:10PM	Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones (Business Wire)
Dec-31-24 04:48PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Dec-19-24 07:00AM	Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Dec-18-24 07:00AM	Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer (Business Wire) -6.28%
Nov-29-24 04:44PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 04:00PM	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.42%
07:00AM	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
Nov-16-24 09:00AM	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
04:00PM	Loading…
Nov-06-24 04:00PM	Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 07:00AM	Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-01-24 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Oct-17-24 07:27AM	Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials (TipRanks)
Oct-16-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome (Business Wire) +6.43%
Sep-30-24 05:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Business Wire)
07:00AM	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases (Business Wire)
Sep-19-24 07:00AM	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue (Business Wire)
Aug-30-24 05:44PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-24 04:00PM	Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -7.84%
Aug-19-24 07:00AM	Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors (Business Wire)
Aug-13-24 07:00AM	Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Aug-01-24 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
05:25PM	Loading…
Jul-31-24 05:25PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-24 01:24AM	Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-09-24 09:52AM	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag (Zacks)
07:34AM	Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment (Pharmaceutical Business Review)
Jul-08-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +9.35%
Jun-28-24 05:00PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.70%
Jun-24-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Business Wire) +9.49%
Jun-21-24 11:10AM	Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-05-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis (Business Wire) +5.88%
May-31-24 05:41PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference (Business Wire) -7.05%
May-14-24 09:54PM	ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 (InvestorPlace) -7.64% +5.26%
04:01PM	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
10:00AM	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
May-07-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-30-24 05:10PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.29%
Apr-22-24 04:30PM	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Business Wire)
Apr-08-24 07:00AM	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Apr-04-24 08:38AM	Why Adicet Bio (ACET) Stock Might be a Great Pick (Zacks)
Apr-01-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-24 05:19PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:35AM	Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +7.35%
Mar-19-24 09:53PM	ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023 (InvestorPlace) +5.42%
04:10PM	Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Mar-15-24 09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Mar-11-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 07:46PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-28-24 09:40AM	Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-12-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-05-24 04:01PM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-31-24 04:39PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-30-24 12:51PM	Hedge Fund and Insider Trading News: Larry Robbins, Ray Dalio, Two Sigma Investments, Point72 Asset Management, Bluebell Capital Partners, Adicet Bio Inc (ACET), Netflix, Inc. (NFLX), and More (Insider Monkey)
Jan-25-24 04:01PM	Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (Business Wire)
09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-22-24 11:43PM	Adicet Bio, Inc. Announces Pricing of Public Offering (Business Wire)
04:28PM	Adicet Bio, Inc. Announces Proposed Public Offering (Business Wire)
Jan-04-24 07:00AM	Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 (Business Wire) +22.73%
Jan-03-24 04:01PM	Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook (Business Wire) -12.44%
Dec-29-23 04:50PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.62% +6.35%
Dec-10-23 12:00PM	Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-08-23 04:10PM	Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire) -6.02%
Nov-07-23 07:00AM	Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference (Business Wire) -8.04%
Nov-02-23 09:00AM	Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire) +13.85%
Oct-31-23 06:25PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-04-23 12:00PM	Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference (Business Wire)
Sep-29-23 05:24PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-23 09:00AM	Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (Business Wire)
Aug-31-23 04:35PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.11%
Aug-12-23 08:16AM	Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely? (Simply Wall St.)
Aug-09-23 04:15PM	Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire) +11.90%
Aug-02-23 04:00PM	Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-31-23 04:50PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.24%
Jul-11-23 08:30AM	Adicet Announces Appointment of Katie Peng to the Board of Directors (Business Wire)
Jun-30-23 04:51PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19% +12.35%
Jun-26-23 04:00PM	Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma (NHL) (Business Wire) -54.29%
Jun-01-23 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference (Business Wire) -5.20%
May-31-23 04:53PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 06:00AM	Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting (Business Wire)
May-09-23 04:30PM	Adicet Bio to Present at the 2023 JMP Securities Life Sciences Conference (Business Wire)
04:10PM	Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Apr-28-23 05:13PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-17-23 06:58AM	Adicet Bio, Inc.'s (NASDAQ:ACET) Price Is Out Of Tune With Revenues (Simply Wall St.) +9.45%
Apr-13-23 07:00AM	Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire) +9.68%
Apr-04-23 02:47PM	Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound (TipRanks) -6.14%
Mar-31-23 04:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 04:01PM	Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kauffman Michael	Director	Jun 05 '24	Sale	1.43	5,900	8,437	5,900	Jun 07 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACET

Adicet Bio Inc

Upgrade your FINVIZ experience